Trials / Recruiting
RecruitingNCT06718816
Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
A Long-term Follow-up Study to Evaluate the Safety and Effectivity of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Mecular Degeneration (wAMD)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 21 (estimated)
- Sponsor
- Beijing Anlong Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.
Conditions
Timeline
- Start date
- 2024-12-09
- Primary completion
- 2029-06-30
- Completion
- 2029-06-30
- First posted
- 2024-12-05
- Last updated
- 2024-12-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06718816. Inclusion in this directory is not an endorsement.